AccuRna

Executive Summary

AccuRna is a Japanese biotechnology company pioneering nucleic acid therapeutics with a focus on innovative drug delivery systems (DDS). Founded in 2015 and headquartered in Tokyo, the company addresses the critical bottleneck in nucleic acid drug development—efficient and targeted delivery. Their proprietary platform enables the delivery of both short-chain (ASO, siRNA, miRNA) and long-chain (mRNA) nucleic acid therapeutics, positioning them to tackle refractory diseases in oncology and infectious disease. With $4.2 million raised and a preclinical-stage pipeline, AccuRna aims to unlock the therapeutic potential of nucleic acids through robust delivery solutions. The company's core technology differentiates itself by providing versatile delivery capabilities that can adapt to various nucleic acid modalities, a key advantage in a field where delivery remains the primary hurdle. AccuRna's platform addresses the limitations of existing delivery methods, such as lipid nanoparticles and viral vectors, by offering improved stability, tissue specificity, and safety. While still in preclinical stages, AccuRna's approach could significantly expand the range of treatable diseases. With a strong scientific foundation and a clear focus on solving industry challenges, AccuRna represents a promising early-stage opportunity in the rapidly evolving nucleic acid therapeutics landscape.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding to Advance Lead Programs55% success
• Q4 2026Strategic Partnership for Delivery Platform Licensing25% success
• Q2 2026Selection of Lead Candidate for IND-Enabling Studies70% success